Brain Cancer Clinical Trials in San Diego

Showing 21-40 of 101 trials

DAY101 In Gliomas and Other Tumors

NCT03429803

This research study is studying a drug Tovorafenib/DAY101 (formerly TAK-580, MLN2480) as a possible treatment a low-grade glioma that has not responded to other treatments. The name of the study drug involved in this study is: • Tovorafenib/DAY101 (formerly TAK-580, MLN2480)

Low-grade Glioma

Karen D. Wright, MD44 participantsStarted Feb 2018

Los Angeles, California, United States • San Diego, California, United States • San Francisco, California, United States +12 more locations

TERMINATEDPhase 2< 1 mile

Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations

NCT05267106

This is an open-label, monotherapy study of pemigatinib in participants with recurrent glioblastoma (GBM) or other recurrent gliomas, circumscribed astrocytic gliomas, and glioneuronal and neuronal tumors with an activating FGFR1-3 mutation or fusion/rearrangement. This study consists of 2 cohorts, Cohorts A, and B, and will enroll approximately 82 participants into each cohort. Participants will receive pemigatinib 13.5 mg QD on a 2-week on-therapy and 1-week off-therapy schedule as long as they are receiving benefit and have not met any criteria for study withdrawal.

GlioblastomaAdult-type Diffuse Gliomas

Incyte Corporation83 participantsStarted May 2022

Beverly Hills, California, United States • Duarte, California, United States • Fullerton, California, United States +76 more locations

DAY101 In Gliomas and Other Tumors

Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations

Brain Cancer Trials in Other Cities

Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

Evaluation of Fluoxetine and Cytotoxic Lysosomal Stress in Glioma (FLIRT)

PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children

Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline Gliomas

Vemurafenib in Children With Recurrent/Refractory BRAF Gene V600E (BRAFV600E)-Mutant Gliomas

REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma

Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System

A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma

Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)

Phase I Study of APX005M in Pediatric Central Nervous System Tumors

89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors

Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM)

VB-111 in Surgically Accessible Recurrent/Progressive GBM

A Safety Study of RTA 744 in Patients With Recurrent High-Grade Gliomas

Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab in Subjects With Recurrent or Progressive Glioblastoma

A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Glioblastoma or Malignant Glioma

Safety, Pharmacokinetics and Efficacy of Paxalisib (GDC-0084) in Newly-diagnosed Glioblastoma

9-ING-41 in Pediatric Patients With Refractory Malignancies.

Other Conditions in San Diego